Silver Book Fact

Pregalbin, an antiepileptic drug, produced around a 32% pain reduction (a significant reduction) at week 16 versus around 20% for placebo, in patients with neuropathic pain due to spinal cord injury.

Cardenas D, Nieshoff E, Suda K, et al. A Randomized Trial of Pregabalin in Patients with Neuropathic Pain due to Spinal Cord Injury. Neurology. 2013; 80(6): 533-9. http://www.neurology.org/content/early/2013/01/23/WNL.0b013e318281546b.abstract

Reference

Title
A Randomized Trial of Pregabalin in Patients with Neuropathic Pain due to Spinal Cord Injury
Publication
Neurology
Publication Date
2013
Authors
Cardenas D, Nieshoff E, Suda K, et al
Volume & Issue
Volume 80, Issue 6
Pages
533-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Targeting A-type K+ channels in primary sensory neurons could provide a novel mechanism-based therapy for the treatment of bone cancer pain–one of the most severe types of chronic pain.  
  • Topical NSAIDs were found in a meta-analysis to be significantly more effective than placebo in reducing persistent pain from musculoskeletal conditions.  
  • 57% of American adults say they would pay an extra $1 per week in taxes in order to support government research into the causes of and treatment for chronic pain.  
  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • Understanding the role of genetics in pain mechanisms is increasing and the potential now exists to conduct genome-wide screens in model organisms to look for pain-associated genes.